IGF-1vsMelatonin

IGF-1 (Insulin-like Growth Factor 1) is a 70-amino-acid peptide hormone with approximately 50% structural homology to proinsulin. It is primarily produced by hepatocytes in response to growth hormone stimulation, though virtually all tissues produce IGF-1 locally for paracrine/autocrine signaling. Circulating IGF-1 is bound to six IGF binding proteins (IGFBP-1 through IGFBP-6), with approximately 80-90% bound to IGFBP-3 in a ternary complex with the acid-labile subunit (ALS). Only free, unbound IGF-1 (approximately 1-2% of total) can activate receptors.

IGF-1 binds to the IGF-1 receptor (IGF-1R), a heterotetrameric receptor tyrosine kinase structurally similar to the insulin receptor. Ligand binding triggers receptor autophosphorylation and recruitment of insulin receptor substrate (IRS) adaptor proteins, activating two major downstream cascades. The PI3K/Akt/mTOR pathway drives protein synthesis (through mTORC1 activation of S6K1 and inhibition of 4E-BP1), cell survival (through BAD phosphorylation and Bcl-2 family regulation), and glucose uptake (through GLUT4 translocation). The Ras/Raf/MEK/ERK pathway promotes cell proliferation, differentiation, and gene expression changes required for tissue growth.

In skeletal muscle, IGF-1's effects include both hypertrophy (enlargement of existing muscle fibers through increased protein synthesis) and hyperplasia (generation of new muscle cells through satellite cell activation and differentiation). Local muscle-derived IGF-1 isoforms (including the MGF splice variant) play a particularly important role in exercise-induced muscle adaptation. The very short half-life of free IGF-1 (10-20 minutes) means that therapeutic administration requires frequent dosing or modified forms (such as IGF-1 LR3 with its extended half-life). Native IGF-1 also binds the insulin receptor (with lower affinity), which contributes to its hypoglycemic effects — a significant clinical risk that requires careful glucose monitoring and administration with food.

Melatonin (N-acetyl-5-methoxytryptamine) is synthesized in the pineal gland from serotonin through a two-step pathway: N-acetyltransferase (AANAT) converts serotonin to N-acetylserotonin, and hydroxyindole O-methyltransferase (HIOMT) converts it to melatonin. AANAT activity is under direct control of the suprachiasmatic nucleus (SCN) master circadian clock — it is strongly suppressed by light (via the retinohypothalamic tract) and activated in darkness, creating the characteristic nocturnal melatonin surge that signals nighttime to every cell in the body.

Melatonin acts through two high-affinity G protein-coupled receptors: MT1 (MTNR1A) and MT2 (MTNR1B), both of which are Gi/o-coupled, inhibiting adenylyl cyclase and reducing cAMP when activated. MT1 receptors in the SCN mediate the acute sleep-promoting effect — their activation inhibits the firing rate of SCN neurons, reducing the alerting signal from the master clock and promoting sleepiness. MT2 receptors in the SCN mediate circadian phase-shifting — their activation during the biological evening advances the clock phase (useful for jet lag and delayed sleep phase), while activation during the biological morning delays it. This dual receptor mechanism explains why melatonin both promotes acute sleepiness and shifts circadian timing.

Beyond sleep, melatonin is one of the most potent endogenous antioxidants. It directly scavenges hydroxyl radicals, superoxide anions, hydrogen peroxide, and peroxynitrite through electron donation. Uniquely, melatonin's antioxidant cascade is amplified — its metabolites (cyclic 3-hydroxymelatonin, AFMK, AMK) are themselves antioxidants, so each melatonin molecule can neutralize up to 10 reactive oxygen species in a cascade. Melatonin also upregulates antioxidant enzymes (superoxide dismutase, glutathione peroxidase, catalase) and downregulates pro-oxidant enzymes (nitric oxide synthase, lipoxygenase). In the immune system, MT1 receptors on T helper cells, natural killer cells, and eosinophils modulate immune function — melatonin generally enhances Th1 cellular immunity, increases NK cell activity, and augments antibody responses to vaccination, which has led to interest in melatonin as an immunomodulator in aging and cancer.